Drugs / VEMTOBERANT
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05139615 | Dec 2021 → Sep 2022 | symptomatic heart failure | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VEMTOBERANT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314946 ↗ |
| Known as | APD418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05139615 ↗ |
| Modality | Small molecule | — CHEMBL5314946 ↗ |
| Route | Intravenous | “Participants will receive a single dose of APD418 as an intravenous (IV) infusion.” NCT05139615 ↗ |